|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3620 EUR | 0.00% |
|
0.00% | +21.68% |
| 07-01 | Nicox Submits NCX 470 New Drug Application In The United States | CI |
| 07-01 | Nicox files U.S. marketing approval application |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 38.72M | - | - | - | ||
| 317B | |||||
| 72.2B | |||||
| 11.7B | |||||
| 8.45B | |||||
| 4.75B |
- Stock Market
- Stocks
- ALCOX Stock
- NXOA Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
